|
Medication
|
Enrollment source
|
Number of patients
|
Number (%) taking rescue medication
|
Duration (days)a
|
|---|
|
Mean
|
SD
|
Median
|
|---|
|
Lithium
|
De novo
|
379
|
28 (7.4)
|
147.9
|
101.8
|
131.5
|
|
Rollover
|
85
|
0
|
–
|
–
|
–
|
|
Total
|
464
|
28 (6.0)
|
147.9
|
101.8
|
131.5
|
|
Valproate
|
De novo
|
379
|
35 (9.2)
|
114.5
|
96.6
|
100
|
|
Rollover
|
85
|
1 (1.2)
|
84.0
|
–
|
84.0
|
|
Total
|
464
|
36 (7.8)
|
113.7
|
95.4
|
92.0
|
- Rescue medication (lithium [immediate or controlled release] or valproate [immediate or extended release]) was recommended for patients not meeting stability criteria. Only one type of rescue medication was permitted at a time. Patients meeting stability criteria were not eligible for rescue medication
- AOM 400 aripiprazole once-monthly 400 mg, SD standard deviation
- aCalculated for patients receiving AOM 400 during maintenance phase who took rescue medication during maintenance phase
